An interventional study of Toothpaste Containing 20% Hydroxyapatite and 2% Calcium Hypophosphite and Stannous Fluoride Toothpaste in Dentin Hypersensitivity, sponsored by Dr. August Wolff GmbH & Co. KG Arzneimittel. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Dr. August Wolff GmbH & Co. KG Arzneimittel · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Dentin Sensitivity with a site in Brazil — 5 open to participants now, 8 under way, 2 of them phase 3. Dentin Sensitivity · Brazil.
Among the 47 studies in Dentin Sensitivity with a site in Brazil, this one is the 2nd largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2026, is one of 32 with no phase, and was the 47th registered.
290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.
Browse Dentin Sensitivity studies →5 of the 47 studies in Dentin Sensitivity with a site in Brazil are open now. Recruiting first, the newest first:
Colgate Palmolive · Sites in Brazil
Ages 18–70
University of Sao Paulo · Sites in Brazil
Ages 6–12
Universidade Federal do Para · Sites in Brazil
Ages 18–40
Universidade Federal do Para · Sites in Brazil
Ages 18–40 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 18 Dentin Sensitivity studies recruiting now, 6 (33%) set no upper age limit and 11 (61%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 6 · Phase 4 6
First in 2009; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 186 is above the median of 60 across 280 interventional studies indexed under Dentin Sensitivity.
Median enrollment 52 across the 46 interventional studies, 40 across the 1 observational. Of the 37 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 47 have an industry lead sponsor. The 10 most frequent:
Dr. August Wolff GmbH & Co. KG Arzneimittel is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Dr. August Wolff GmbH & Co. KG Arzneimittel has 1 study filed under Dentin Sensitivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Dentin Sensitivity with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07939620Dr. August Wolff GmbH & Co. KG ArzneimittelNon-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin Hypersensitivity | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies in Dentin Sensitivity with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center, randomized, double-blind, three-arm, non-inferiority clinical study will evaluate whether a toothpaste containing 20% hydroxyapatite and 2% calcium hypophosphite is clinically non-inferior to each of two active comparator toothpastes in reducing dentin hypersensitivity. One comparator contains stannous fluoride and the other contains 8% arginine. The study will also evaluate the safety and tolerability of the three toothpastes.
A total of 186 adults aged 18 to 65 years with dentin hypersensitivity will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. Participants will use their assigned toothpaste twice daily for 56 days.
The primary outcome is the mean reduction in dentin hypersensitivity symptoms from baseline to Day 56, as measured by the airblast test score using a 0-to-100 mm visual analogue scale (VAS), comparing the test group separately with each of the two control groups.
Additional assessments include responses to the airblast and cold-water tests after the first toothpaste use and during follow-up, participants' subjective assessments of dentin sensitivity, adverse events, and investigator- and participant-rated efficacy and tolerability.
Only the main outcome measures and the main inclusion and exclusion criteria are listed in this record. Further secondary and exploratory endpoints as well as the complete eligibility criteria are specified in the study protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Only the main eligibility criteria are listed. The complete criteria are specified in the study protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Toothpaste Containing 20% Hydroxyapatite and 2% Calcium Hypophosphite
Device: Stannous Fluoride Toothpaste
Device: 8% Arginine Toothpaste
Participants will use the assigned toothpaste twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.
Participants will use a comparator toothpaste containing stannous fluoride, providing 1100 ppm fluoride, twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.
Participants will use a comparator toothpaste containing 8% arginine twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.
Mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56
The primary endpoint is the mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS \[0-100\]) from Baseline to Day 56 between the test group and both control groups. VAS: 0 mm: No sensitivity; 100 mm: worst imaginable sensitivity. Non-inferiority will be assessed separately for the investigational toothpaste versus each of the two comparator toothpastes, using a predefined non-inferiority margin (δ) of 10 mm on the VAS scale (0-100 mm).
Time frame: Baseline (Day 1) to Day 56 (±3 Days)
Mean change in VAS (Cold Water Test) from Baseline to Day 56
Mean change in VAS (Cold Water Test) from Baseline to Day 56 between the test group and each of the two control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).
Time frame: Baseline (Day 1) to Day 56 (±3 Days)
Mean change in VAS (Airblast test) from Baseline to Day 28
Mean change in VAS (Airblast test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).
Time frame: Baseline (Day 1) to Day 28 (±3 Days)
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).
Time frame: Day 1 (Baseline and directly after the first application)
Mean change in VAS (Cold Water test) from Baseline to Day 28
Mean change in VAS (Cold Water Test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).
Time frame: Baseline (Day 1) to Day 28 (±3 Days)
Mean change in VAS (Cold Water test) from Baseline to Day 1 directly after the first application
Mean change in VAS (Cold Water Test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).
Time frame: Day 1 (Baseline and directly after the first application)
Plan to share: No — All data and information retrieved within the investigation are an intellectual property of the Sponsor.
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jan 2027, 2 months after the start.
Of 33 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's planned 2 months is below that.
Counting every sponsor, half of 144 studies reached it within 6 months; a quarter within 3 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. August Wolff GmbH & Co. KG Arzneimittel